Opinion
Video
Author(s):
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma